Drug Profile
F 14258
Latest Information Update: 14 Dec 2006
Price :
$50
*
At a glance
- Originator Pierre Fabre
- Class Antidepressants; Anxiolytics
- Mechanism of Action Serotonin 1B receptor antagonists; Serotonin 1D receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Major depressive disorder; Obsessive-compulsive disorders
Most Recent Events
- 14 Jun 2002 No development reported - Preclinical for Depression in France (PO)
- 14 Jun 2002 No development reported - Preclinical for Obsessive-compulsive disorders in France (PO)
- 16 May 2001 Pierre Fabre has merged with bioMérieux Alliance